Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma

[1]  Jeffrey E. Lee,et al.  Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness , 2017, The Journal of clinical endocrinology and metabolism.

[2]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[3]  M. Kattan,et al.  Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer , 2015, Annals of Surgical Oncology.

[4]  M. Banerjee,et al.  The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. , 2014, The Journal of clinical endocrinology and metabolism.

[5]  Kathryn J. Rowland,et al.  Biochemical Cure after Reoperations for Medullary Thyroid Carcinoma: A Meta-analysis , 2014, Annals of Surgical Oncology.

[6]  Herb Chen,et al.  Current understanding and management of medullary thyroid cancer. , 2013, The oncologist.

[7]  H. Dralle,et al.  Surgical management of the lateral neck compartment for metastatic thyroid cancer , 2013, Current opinion in oncology.

[8]  H. Dralle,et al.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[9]  S. Hauptmann,et al.  Prediction of lateral lymph node metastases in medullary thyroid cancer , 2008, The British journal of surgery.

[10]  S. Hauptmann,et al.  Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. , 2007, Archives of surgery.

[11]  S. Roman,et al.  Prognosis of medullary thyroid carcinoma , 2006, Cancer.

[12]  F. Kraeber-Bodéré,et al.  Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  K. Owzar,et al.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. , 2005, The New England journal of medicine.

[14]  H. Holzhausen,et al.  Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. , 2005, The Journal of clinical endocrinology and metabolism.

[15]  H. Dralle,et al.  Early malignant progression of hereditary medullary thyroid cancer. , 2003, The New England journal of medicine.

[16]  Jeffrey E. Lee,et al.  Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. , 2003, Archives of surgery.

[17]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[18]  D. Clayton,et al.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC , 1994, Nature Genetics.

[19]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[20]  J. Ritz,et al.  Activation of a novel human transforming gene, ret, by DNA rearrangement , 1985, Cell.

[21]  J. Norton,et al.  Localization and resection of clinically inapparent medullary carcinoma of the thyroid. , 1980, Surgery.